Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis?

References

• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63:8-160
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Passalacqua G. Emerging anti-inflammatory agents for allergic rhinitis. Expert Opin Emerg Drugs 2005;10:689-705
   PubMedGoogle Scholar
• Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl 85):17-25
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I, Vizzaccaro A, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life?. Allergy 2005;60:882-7
   PubMed Web of Science ®Google Scholar
• Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007;28:3-9
   PubMed Web of Science ®Google Scholar
• Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc 2007;28:393-7
   PubMed Web of Science ®Google Scholar
• Scadding GK, Williams A. The burden of allergic rhinitis as reported by UK patients compared with their doctors. Rhinology 2008;46:99-106
   PubMed Web of Science ®Google Scholar
• Leynaert B, Neukirch C, Liard R, et al. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000;162:1391-6
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Nathan RA, Selner JC, et al. Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 1997;99:S815-19
   Web of Science ®Google Scholar
• Pratt EL, Craig TJ. Assessing outcomes from the sleep disturbance associated with rhinitis. Curr Opin Allergy Clin Immunol 2007;7:249-56
   PubMed Web of Science ®Google Scholar
• Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: Case-control study. J Allergy Clin Immunol 2007;120:381-7
   PubMed Web of Science ®Google Scholar
• Nihlen U, Greiff L, Montnemery P, et al. Incidence and remission of self-reported allergic rhinitis symptoms in adults. Allergy 2006;61:1299-304
   PubMed Web of Science ®Google Scholar
• European Federation of Allergy and Airway Diseases Patient Association. Results of the patient voice allergy survey: Impact of allergic rhinitis in Europe. Summary report. Available at: http://www.efanet.org/enews/documents/AllergysummaryreportFINALdata220605-onsitea.doc. 2005
   Google Scholar
• Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518
   PubMed Web of Science ®Google Scholar
• Task Force on Allergic Disorders. The Allergy Report. Volume 1. 2000. Milwaukee, WI, American Academy of Allergy, Asthma and Immunology. Available at: http://www.theallergyreport.com. [Last accessed 21 June 2007]
   Google Scholar
• Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317:1624-9
   PubMed Web of Science ®Google Scholar
• Loth S, Bende M. Effect of nasal anaesthesia on lacrimal function after nasal allergen challenge. Clin Exp Allergy 1994;24:375-6
   PubMed Web of Science ®Google Scholar
• Sheahan P, Walsh RM, Walsh MA, et al. Induction of nasal hyper-responsiveness by allergen challenge in allergic rhinitis: the role of afferent and efferent nerves. Clin Exp Allergy 2005;35:45-51
   PubMed Web of Science ®Google Scholar
• Baroody FM, Foster KA, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:194-9
   PubMed Web of Science ®Google Scholar
• Naclerio RM, Pinto J, deTineo M, et al. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc 2008;29:24-8
   PubMed Web of Science ®Google Scholar
• Baroody FM, Shenaq D, deTineo M, et al. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 2009;123:1342-8
   PubMed Web of Science ®Google Scholar
• Naclerio R. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg 2008;138:129-39
   PubMed Web of Science ®Google Scholar
• Blaiss MS. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids. Curr Med Res Opin 2008;24:821-36
   PubMed Web of Science ®Google Scholar
• Bielory L. Intranasal corticosteroids reduce ocular symptoms of allergic rhinitis as a class effect. J Allergy Clin Immunol 2008;121:538-9
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Trial number: 05-3011; Available at: www.fda.gov./cder/approval/index.htm. [Last accessed 24 April 2009]
   Google Scholar
• Newson-Smith G, Powell M, Baehre M, et al. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol 1997;254:236-41
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Trial number: 05-3006; Available at: www.fda.gov./cder/approval/index.htm. [Last accessed 24 April 2009]
   Google Scholar
• AstraZeneca. Trial number: 05-3030; Available at: www.fda.gov./cder/approval/index.htm. [Last accessed 24 April 2009]
   Google Scholar
• Stern MA, Dahl R, Nielsen LP, et al. A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997;11:323-30
   PubMedGoogle Scholar
• Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002;57:586-91
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Trial number: 05-3038; Available at: www.fda.gov./cder/approval/index.htm. [Last accessed 24 April 2009]
   Google Scholar
• Andersson M, Lindqvist N, Svensson C, et al. Dry powder inhalation of budesonide in allergic rhinitis. Clin Otolaryngol Allied Sci 1993;18:30-3
   PubMed Web of Science ®Google Scholar
• Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006;118:1142-8
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007;62:1078-84
   PubMed Web of Science ®Google Scholar
• Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119:1430-7
   PubMed Web of Science ®Google Scholar
• Jacobs R, Martin B, Hampel F, et al. Effectiveness of fluticasone furoate 110 µg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin 2009;25:1393-401
   PubMed Web of Science ®Google Scholar
• Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007;28:216-25
   PubMed Web of Science ®Google Scholar
• Andrews CP, Martin BG, Jacobs RL, et al. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc 2009;30:128-38
   PubMed Web of Science ®Google Scholar
• Amar NJ, Kaiser H, Vandewalker M, et al. Fluticasone furoate nasal spray provides better relief from the nighttime symptoms of seasonal allergic rhinitis (SAR) than oral fexofenadine. Presented at the American College of Allergy, Asthma & Immunology Annual Meeting, Seattle, WA, November 6-11, 2008
   Google Scholar
• Naclerio R, Kaiser H, Lumry W, et al. Fluticasone furoate nasal spray provided 24-hour relief of nasal and ocular symptoms of seasonal allergic rhinitis (SAR) caused by ragweed. Presented at the XXVI Congress of the European Academy of Allergology and Clinical Immunology, Göteborg, Sweden, June 9-13, 2007; Abstract 353
   Google Scholar
• Stricker WE, Nathan RA, Winder JA, et al. Fluticasone propionate aqueous nasal spray (FP) and loratadine (LOR), alone and in combination, in the treatment of fall seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 1998;80:115
   Google Scholar
• van Bavel JH, Ratner PH, Nayak AS, et al. Ocular efficacy and clinician overall evaluation of intranasal fluticasone propionate (FP) versus loratadine (LOR) in seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 1997;78:128
   Google Scholar
• GlaxoSmithKline. Trial number: FLN-305; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
   Google Scholar
• GlaxoSmithKline. Trial number: FNM30034; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
   Google Scholar
• Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952-7
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Trial number: FNM30019; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
   Google Scholar
• Ortolani C, Foresi A, Di Lorenzo G, et al. A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis. FLNCO2 Italian Study Group. Allergy 1999;54:1173-80
   Google Scholar
• Schering-Plough. Trial number: P03431; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
   Google Scholar
• Berkowitz RB, Roberson S, Zora J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 1999;20:167-72
   PubMed Web of Science ®Google Scholar
• Bronsky EA, Aaronson DW, Berkowitz RB, et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:51-6
   PubMed Web of Science ®Google Scholar
• Schering-Plough. Trial number: C92-011; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
   Google Scholar
• Schering-Plough. Trial number: C93-013; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
   Google Scholar
• Schering-Plough. Trial number: C93-184; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
   Google Scholar
• Schering-Plough. Trial number: P04608; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
   Google Scholar
• Schering-Plough. Trial number: I94-001; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
   Google Scholar
• Schering-Plough. Trial number: C94-145; Available at: www.fda.gov/cder/foi/nda. [Last accessed 24 April 2009]
   Google Scholar
• Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:264-71
   PubMed Web of Science ®Google Scholar
• Schering-Plough. Trial number: P05067; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
   Google Scholar
• Prenner B, Shekar T, Teper A. Once-daily mometasone furoate nasal spray reduces ocular symptoms associated with seasonal allergic rhinitis. Presented at the XXVII Congress of the European Academy of Allergology and Clinical Immunology, Barcelona, Spain, June 7-11, 2008; Abstract 995
   Google Scholar
• Schering-Plough. Trial number: P05106; Available at: www.clinicalstudyresults.org. [Last accessed 24 April 2009]
   Google Scholar
• Hebert J, Danzig M, Gates D. Mometasone furoate improves total ocular symptom score in patients with allergic rhinitis. J Allergy Clin Immunol 2007;119[1 Suppl]:S61. Abstract 240
   Web of Science ®Google Scholar
• Munk ZM, Gross GN, Hampel FC Jr, et al. Preseasonal, once daily triamcinolone acetonide nasal aerosol for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;78:325-31
   PubMed Web of Science ®Google Scholar
• Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Clin Ther 1995;17:252-63
   PubMed Web of Science ®Google Scholar
• Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008;100:272-9
   PubMed Web of Science ®Google Scholar
• Schenkel E, LaForce C, Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis -- Effective in relieving ocular symptoms. Allergy Clin Immunol Int 2007;19:50-3
   Web of Science ®Google Scholar
• Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000;106:S179-90
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 2000;55:16-33
   PubMed Web of Science ®Google Scholar
• Bernstein D. Long-term ocular safety of mometasone furoate nasal spray during treatment of perennial allergic rhinitis. Presented at the XXVII Congress of the European Academy of Allergology and Clinical Immunology, Barcelona, Spain, June 7-11, 2008; Abstract 194
   Google Scholar
• Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg 2003;129:739-50
   PubMed Web of Science ®Google Scholar
• Allen A, Down G, Newlands A, et al. Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects. Ann Allergy Asthma Immunol 2007;98:A89
   PubMed Web of Science ®Google Scholar
• Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007;62:1071-7
   PubMed Web of Science ®Google Scholar
• Wagenmann M, Baroody FM, Desrosiers M, et al. Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D2. Clin Exp Allergy 1996;26:371-8
   PubMed Web of Science ®Google Scholar
• Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L660-7
   PubMed Web of Science ®Google Scholar
• Valotis A, Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 2007;8:54
   PubMed Web of Science ®Google Scholar